Adenosine, nicotinic acid, phospholipids, vitamin b6 (Lipostabil)
Adenosine, nicotinic acid, phospholipids, vitamin b6
Rhone-poulenc Rorer SA (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Rhone-poulenc Rorer SA (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lipostabil EACH 10 ML CONTAINS ADENOSINE PHOSPHATE A 2,0 MG NICOTINIC ACID A 2,0 mg PHOSPHOLIPIDS A 500,0 mg VITAMIN B6 A 4,0 mg | Not listed | H0656 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Adenosine
Consolidated Schedules 06 July 2026, line 5146
S4: Niacin
- and derivatives thereof
- when intended for hypercholesterolaemia and for the management of dyslipidaemias; (S0)
- except in oral preparations or mixtures containing more than 35 mg of Niacin per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 7247 to 7252
S4: Phospholipids
- when intended for parenteral administration.
Consolidated Schedules 06 July 2026, line 7554
S3: Vitamin b6
- and derivatives thereof
- in preparations thereof for injection; (S0)
- except in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S1)
Consolidated Schedules 06 July 2026, lines 4421 to 4426
S1: Niacin
- and derivatives thereof
- in oral preparations or mixtures containing more than 35 mg of Niacin per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except when intended for hypercholesterolaemia and for the management of dyslipidaemias. (S4)
Consolidated Schedules 06 July 2026, lines 879 to 884
S1: Phospholipids
- when applied for therapeutic purposes.
Consolidated Schedules 06 July 2026, line 1016
S1: Vitamin b6
- and derivatives thereof
- in oral preparations or mixtures containing more than 100 mg of Vitamin B6 per recommended daily dose alone or in combination with other active pharmaceutical ingredients; (S0)
- except in preparations thereof for injection. (S3)
Consolidated Schedules 06 July 2026, lines 1170 to 1175
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.